Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHATHABISH SHIMOGA KARIYANNA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1346683869
CMS profile
4226562
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$5,458.05

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Biohaven Pharmaceutical Holding Company Ltd. $5,290.38 5
Lilly USA, LLC $94.80 1
ABBVIE INC. $61.17 1
Amgen Inc. $11.70 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHATHABISH SHIMOGA KARIYANNA

NPI 1346683869 · CMS profile ID 4226562

Allopathic & Osteopathic Physicians / Family Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346683869?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHATHABISH SHIMOGA KARIYANNA, NPI 1346683869, CMS profile ID 4226562. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346683869?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SHATHABISH SHIMOGA KARIYANNA, NPI 1346683869, CMS profile ID 4226562. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346683869?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SHATHABISH SHIMOGA KARIYANNA, NPI 1346683869, CMS profile ID 4226562, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1346683869?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $5,458.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $11.7011/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939199005 CMS
Biohaven Pharmaceutical Holding Company Ltd. $2,550.0009/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923632971 CMS
Biohaven Pharmaceutical Holding Company Ltd. $124.9909/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923632973 CMS
Biohaven Pharmaceutical Holding Company Ltd. $2,550.0008/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923632967 CMS
Biohaven Pharmaceutical Holding Company Ltd. $57.3908/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923632969 CMS
ABBVIE INC. $61.1708/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893014461 CMS
Lilly USA, LLC $94.8005/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918339971 CMS
Biohaven Pharmaceutical Holding Company Ltd. $8.0005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923632965 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $211.78 8
PY2020 $1,312.49 4
PY2021 $14,868.25 19
PY2022 $5,458.05 8
PY2023 $546.37 12
PY2024 $741.68 18
PY2025 $5,876.53 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $64,380.00 28
PY2022 Principal investigator $4,896.50 4
PY2021 Principal investigator $18,781.00 5
PY2020 Principal investigator $2,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $2,436.00 12/24/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287934
Principal investigator 1 Ipsen Innovation $3,444.00 12/11/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287930
Principal investigator 1 Ipsen Innovation $735.00 12/11/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287932
Principal investigator 1 Ipsen Innovation $735.00 12/11/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287936
Principal investigator 1 Ipsen Innovation $3,192.00 12/11/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287938
Principal investigator 1 Ipsen Innovation $770.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287908
Principal investigator 1 Ipsen Innovation $3,444.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287910
Principal investigator 1 Ipsen Innovation $3,000.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287912
Principal investigator 1 Ipsen Innovation $3,444.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287914
Principal investigator 1 Ipsen Innovation $1,365.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287916
Principal investigator 1 Ipsen Innovation $1,078.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287918
Principal investigator 1 Ipsen Innovation $200.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287920
Principal investigator 1 Ipsen Innovation $2,500.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287922
Principal investigator 1 Ipsen Innovation $665.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287924
Principal investigator 1 Ipsen Innovation $4,214.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287926
Principal investigator 1 Ipsen Innovation $3,444.00 11/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287928
Principal investigator 1 Ipsen Innovation $3,444.00 10/22/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287906
Principal investigator 1 Ipsen Innovation $1,000.00 10/17/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287904
Principal investigator 1 Ipsen Innovation $3,444.00 09/29/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287902
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287894
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287896
Principal investigator 1 Ipsen Innovation $4,000.00 08/28/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287898
Principal investigator 1 Ipsen Innovation $126.00 08/19/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287900
Principal investigator 1 Ipsen Innovation $1,000.00 07/14/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287890
Principal investigator 1 Ipsen Innovation $200.00 07/14/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287892
Principal investigator 1 Ipsen Innovation $1,500.00 06/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287884
Principal investigator 1 Ipsen Innovation $10,000.00 06/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287886
Principal investigator 1 Ipsen Innovation $3,000.00 06/27/2025 Non-covered Recipient Entity
Michigan Headache And Neurological Institute
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287888